DUSA Pharmaceuticals

DUSA Pharmaceuticals is a biotechnology company founded in 1991, with a focus on advancing its Levulan photodynamic therapy (PDT) technology platform. This platform is used in conjunction with the exclusive BLU-U Blue Light Photodynamic Therapy Illuminator. The company has obtained approval from the U.S. FDA for the use of Levulan Kerastick for treating minimally to moderately thick actinic keratoses (AKs) on the face or scalp, a condition often diagnosed by U.S. dermatologists. DUSA's PDT involves a two-part process, making target cells highly sensitive to light, followed by exposure to blue light, resulting in the eradication of the cells. Furthermore, the BLU-U device is utilized to treat mild to moderate inflammatory acne.

DUSA Pharmaceuticals stands out in the industry with its focus on leveraging light to heal the skin. The company is headquartered in Wilmington, MA. Thus far, there is no publicly available information about the last investment and the associated investors for DUSA Pharmaceuticals. With a strong foundation and innovative approach, DUSA Pharmaceuticals is positioned to make a significant impact in the field of dermatological therapies.